FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1944458049> ?p ?o ?g. }

• W1944458049 endingPage "39" @default.
• W1944458049 startingPage "31" @default.
• W1944458049 abstract "In resource‐constrained countries where the prevalence of hepatitis C virus (HCV) disease is usually high, it is important to know which population should be treated first in order to increase treatment effectiveness. The aim was to estimate the effectiveness of different HCV treatment eligibility scenarios in three different countries. Using a Markov model, we estimated the number of life‐years saved (LYS) with different treatment eligibility scenarios according to fibrosis stage (F1‐F4 or F3‐4), compared to base case (F2‐F4), at a constant treatment rate, of patients between 18 and 60 years of age, at stages F0/F1 to F4, without liver complications or coinfections, chronically infected by HCV, and treated with pegylated interferon (IFN)/ribavirin or more‐efficacious therapies (i.e. IFN free). We conducted the analysis in Egypt (prevalence = 14.7%; 45,000 patients treated/year), Thailand (prevalence = 2.2%; 1,000 patients treated/year), and Côte d'Ivoire (prevalence = 3%; 150 patients treated/year). In Egypt, treating F1 patients in addition to ≥F2 patients (SE1 vs. SE0) decreased LYS by 3.9%. Focusing treatment only on F3‐F4 patients increased LYS by 6.7% (SE2 vs. SE0). In Thailand and Côte d'Ivoire, focusing treatment only on F3‐F4 patients increased LYS by 15.3% and 11.0%, respectively, compared to treating patients ≥F2 (ST0 and SC0, respectively). Treatment only for patients at stages F3‐F4 with IFN‐free therapies would increase LYS by 16.7% versus SE0 in Egypt, 22.0% versus ST0 in Thailand, and 13.1% versus SC0 in Côte d'Ivoire. In this study, we did not take into account the yearly new infections and the impact of treatment on HCV transmission. Conclusion: Our model‐based analysis demonstrates that prioritizing treatment in F3‐F4 patients in resource‐constrained countries is the most effective scenario in terms of LYS, regardless of treatment considered. (Hepatology 2015;62:31‐39)" @default.
• W1944458049 created "2016-06-24" @default.
• W1944458049 creator A5002412618 @default.
• W1944458049 creator A5008312486 @default.
• W1944458049 creator A5017558974 @default.
• W1944458049 creator A5020349855 @default.
• W1944458049 creator A5020713209 @default.
• W1944458049 creator A5026951598 @default.
• W1944458049 creator A5028932019 @default.
• W1944458049 creator A5055055641 @default.
• W1944458049 creator A5060196651 @default.
• W1944458049 creator A5064601780 @default.
• W1944458049 creator A5072014617 @default.
• W1944458049 creator A5072596897 @default.
• W1944458049 creator A5081834250 @default.
• W1944458049 creator A5083287436 @default.
• W1944458049 creator A5083960272 @default.
• W1944458049 creator A5089345771 @default.
• W1944458049 date "2015-02-27" @default.
• W1944458049 modified "2023-10-18" @default.
• W1944458049 title "How to optimize hepatitis C virus treatment impact on life years saved in resource‐constrained countries" @default.
• W1944458049 cites W1557711811 @default.
• W1944458049 cites W1591742415 @default.
• W1944458049 cites W1829380874 @default.
• W1944458049 cites W1881009043 @default.
• W1944458049 cites W1964051982 @default.
• W1944458049 cites W1972072196 @default.
• W1944458049 cites W1977300462 @default.
• W1944458049 cites W1996217966 @default.
• W1944458049 cites W2030711448 @default.
• W1944458049 cites W2042158802 @default.
• W1944458049 cites W2078145079 @default.
• W1944458049 cites W2078251659 @default.
• W1944458049 cites W2082419684 @default.
• W1944458049 cites W2094986548 @default.
• W1944458049 cites W2116187238 @default.
• W1944458049 cites W2117490789 @default.
• W1944458049 cites W2117766751 @default.
• W1944458049 cites W2120948808 @default.
• W1944458049 cites W2135468595 @default.
• W1944458049 cites W2145920352 @default.
• W1944458049 cites W2222306685 @default.
• W1944458049 doi "https://doi.org/10.1002/hep.27691" @default.
• W1944458049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25581111" @default.
• W1944458049 hasPublicationYear "2015" @default.
• W1944458049 type Work @default.
• W1944458049 sameAs 1944458049 @default.
• W1944458049 citedByCount "26" @default.
• W1944458049 countsByYear W19444580492015 @default.
• W1944458049 countsByYear W19444580492016 @default.
• W1944458049 countsByYear W19444580492017 @default.
• W1944458049 countsByYear W19444580492018 @default.
• W1944458049 countsByYear W19444580492019 @default.
• W1944458049 countsByYear W19444580492020 @default.
• W1944458049 countsByYear W19444580492021 @default.
• W1944458049 crossrefType "journal-article" @default.
• W1944458049 hasAuthorship W1944458049A5002412618 @default.
• W1944458049 hasAuthorship W1944458049A5008312486 @default.
• W1944458049 hasAuthorship W1944458049A5017558974 @default.
• W1944458049 hasAuthorship W1944458049A5020349855 @default.
• W1944458049 hasAuthorship W1944458049A5020713209 @default.
• W1944458049 hasAuthorship W1944458049A5026951598 @default.
• W1944458049 hasAuthorship W1944458049A5028932019 @default.
• W1944458049 hasAuthorship W1944458049A5055055641 @default.
• W1944458049 hasAuthorship W1944458049A5060196651 @default.
• W1944458049 hasAuthorship W1944458049A5064601780 @default.
• W1944458049 hasAuthorship W1944458049A5072014617 @default.
• W1944458049 hasAuthorship W1944458049A5072596897 @default.
• W1944458049 hasAuthorship W1944458049A5081834250 @default.
• W1944458049 hasAuthorship W1944458049A5083287436 @default.
• W1944458049 hasAuthorship W1944458049A5083960272 @default.
• W1944458049 hasAuthorship W1944458049A5089345771 @default.
• W1944458049 hasBestOaLocation W19444580491 @default.
• W1944458049 hasConcept C126322002 @default.
• W1944458049 hasConcept C146357865 @default.
• W1944458049 hasConcept C151730666 @default.
• W1944458049 hasConcept C203014093 @default.
• W1944458049 hasConcept C2522874641 @default.
• W1944458049 hasConcept C2776408679 @default.
• W1944458049 hasConcept C2776455275 @default.
• W1944458049 hasConcept C2776461080 @default.
• W1944458049 hasConcept C2777075537 @default.
• W1944458049 hasConcept C2780040827 @default.
• W1944458049 hasConcept C2908647359 @default.
• W1944458049 hasConcept C71924100 @default.
• W1944458049 hasConcept C86803240 @default.
• W1944458049 hasConcept C90924648 @default.
• W1944458049 hasConcept C99454951 @default.
• W1944458049 hasConceptScore W1944458049C126322002 @default.
• W1944458049 hasConceptScore W1944458049C146357865 @default.
• W1944458049 hasConceptScore W1944458049C151730666 @default.
• W1944458049 hasConceptScore W1944458049C203014093 @default.
• W1944458049 hasConceptScore W1944458049C2522874641 @default.
• W1944458049 hasConceptScore W1944458049C2776408679 @default.
• W1944458049 hasConceptScore W1944458049C2776455275 @default.
• W1944458049 hasConceptScore W1944458049C2776461080 @default.
• W1944458049 hasConceptScore W1944458049C2777075537 @default.
• W1944458049 hasConceptScore W1944458049C2780040827 @default.

• next